Breaking News


Ustekinumab: Effects on quality of life and sexual difficulties associated with psoriasis


Results from two randomized, placebo-controlled, crossover trials in 1,996 patients with moderate-severe psoriasis treated with ustekinumab were analyzed regarding aspects of quality of life (QoL) and sexual difficulties. QoL was assessed using the Dermatology Life Quality Index (DLQI) and psoriasis severity by the Psoriasis Area and Severity Index (PASI). At baseline the mean DLQI was 12, but at week 12 significant changes were seen in the ustekinumab group (-9.13) versus the placebo group (-0.53; P < 0.001). Impaired sexual function was reported by 22.6% of patients at baseline and at week 12. This had decreased to 2.7% in the ustekinumab patients; there was no change in the placebo group (P < 0.001). Improvements ...

to Continue Reading, Login Now

Please Login

If you are a registered user but you have forgotten your password, please click here
If you are not a registered user, please register here

return to breaking news list